ClinicalTrials.gg
CompletedNCT06742853Updated Nov 10, 2025

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

A Phase 1 interventional study of AZD0780 and Ezetimibe in Dyslipidemia, sponsored by AstraZeneca. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
4th of 11
81 · median 59
Started
2024
with 3 others
Phase 1
8 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 4th largest by enrollment, is one of 4 that started in 2024, is one of 8 in phase 1, and was the 7th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

Read the detailed description

This is a randomized, single-blind, placebo-controlled study in healthy participants with elevated low-density lipoprotein-cholesterol (LDL-C).

This study will assess the pharmacokinetic (PK), safety, tolerability, and efficacy of AZD0780 in combination with ezetimibe, ezetimibe/rosuvastatin, and ezetimibe/bempedoic acid.

Participants will be randomized to receive either AZD0780 or placebo (to be administered with ezetimibe, ezetimibe/rosuvastatin, or ezetimibe/bempedoic acid).

The study will comprise:

  1. A Screening Period of up to 28 days.
  2. A Run-in Period of 28 days.
  3. A Treatment Period of 28 days.
  4. Two Follow-up Visits, one and two weeks after the last dose of study drug.
03

Conditions studied

  • Dyslipidemia

Keywords

  • LDL-C
  • Hypercholesterolemia
  • Cholesterol absorption inhibitor
  • ATP-citrate lyase inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the form before any study-related procedure.
  2. All females must have a negative serum pregnancy test at the Screening Visit and on admission to the Clinical Unit
  3. Females of non- must be confirmed at the Screening Visit by fulfilling one of the following criteria: or surgically sterilized females.
  4. Have a (BMI) > 18 kg/m² and weigh at least 50 kg.
  5. Sexually active fertile male participants with partners of childbearing potential must adhere to the methods.
  6. Fasting LDL-C > 100 mg/dL but \< 190 mg/dL (> 2.6 mmol/L but \< 4.9 mmol/L for London EPCU) at the Screening Visit.
  7. Fasting triglycerides \< 400 mg/dL (or \< 10.3 mmol/L for London EPCU) at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder.
  2. History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  4. Any laboratory values with specific deviations in (ALT), aspartate transaminase (AST), total (TBL), estimated , or at the Screening Visit or on Admission
  5. Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results other than those described under exclusion criterion number 4, at Screening and/or Admission to the Clinical Unit
  6. Any positive result on Screening for serum , hepatitis B core antibody or .
  7. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0780, ezetimibe, rosuvastatin, and bempedoic acid.
  8. Treatment with any lipid-lowering therapy or AZD0780 within the 3 months prior to Screening.
  9. Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to Screening (approved or and apart from AZD0780).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Ezetimibe + AZD0780

    Participants will receive ezetimibe 10 mg and AZD0780 once daily (QD) for 4 weeks.

    Drug: AZD0780 · Drug: Ezetimibe

  • Experimental
    Rosuvastatin + Ezetimibe + AZD0780

    Participants will receive rosuvastatin 20 mg, ezetimibe 10 mg and AZD0780 QD for 4 weeks.

    Drug: AZD0780 · Drug: Ezetimibe · Drug: Rosuvastatin

  • Experimental
    Bempedoic Acid + Ezetimibe + AZD0780 (Optional Cohort)

    Participants will receive bempedoic acid 180 mg, ezetimibe 10 mg and AZD0780 QD for 4 weeks.

    Drug: AZD0780 · Drug: Ezetimibe · Drug: Bempedoic Acid

  • Placebo comparator
    Ezetimibe + Placebo

    Participants will receive ezetimibe 10 mg and placebo QD for 4 weeks.

    Drug: Ezetimibe · Drug: Placebo

  • Placebo comparator
    Rosuvastatin + Ezetimibe + Placebo

    Participants will receive rosuvastatin 20 mg, ezetimibe 10 mg and placebo QD for 4 weeks.

    Drug: Ezetimibe · Drug: Rosuvastatin · Drug: Placebo

  • Placebo comparator
    Bempedoic Acid + Ezetimibe + Placebo (Optional Cohort)

    Participants will receive bempedoic acid 180 mg, ezetimibe 10 mg and placebo QD for 4 weeks.

    Drug: Ezetimibe · Drug: Bempedoic Acid · Drug: Placebo

Interventions

  • AZD0780 tablet will be administered orally.

  • Ezetimibe tablet will be administered orally.

  • Rosuvastatin tablet will be administered orally.

  • Bempedoic Acid tablet will be administered orally.

  • DrugPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Change from baseline in direct Low-density Lipsprotein Cholesterol (LDL-C)

    To evaluate the effect of AZD0780 on LDL-C levels versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  2. Number of participants with adverse events

    The safety and tolerability of AZD0780 when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid will be assessed.

    Time frame: From screening (Day -56 to -29) to 14 Weeks

Secondary outcomes

  1. Plasma concentration of AZD0780

    To further characterize AZD0780 pharmacokinetics (PK) in plasma.

    Time frame: From Day 1 to Day 42

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To further characterize AZD0780 PK in plasma.

    Time frame: From Day 1 to Day 42

  3. Area under concentration-time curve in the dosing interval (AUCtau) (Day 15)

    To further characterize AZD0780 PK in plasma.

    Time frame: From Day 1 to Day 42

  4. Maximum observed drug concentration (Cmax)

    To further characterize AZD0780 PK in plasma.

    Time frame: From Day 1 to Day 42

  5. Time to reach maximum observed concentration (tmax)

    To further characterize AZD0780 PK in plasma.

    Time frame: From Day 1 to Day 42

  6. Change from baseline in LDL-C ultra

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  7. Change from baseline in LDL-C Friedewald

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  8. Change from baseline in total cholesterol

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  9. Change from baseline in non- HDL-C (high-density lipoprotein-cholesterol)

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  10. Change from baseline in HDL-C

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  11. Change from baseline in triglycerides

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  12. Change from baseline in in Lipoprotein A [Lp(a)]

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

  13. Change from baseline in Apolipoprotein B (ApoB)

    To evaluate the effect of AZD0780 on lipid parameters and inflammatory markers versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

    Time frame: Week 4

07

Study locations

3 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Oct 2025, 10 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 10 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 19, 2024
StartActual
Dec 20, 2024
Primary completionActual
Oct 29, 2025
CompletionActual
Oct 29, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742853
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 20, 2024
Primary completion
Oct 29, 2025
Completion
Oct 29, 2025
Last update
Nov 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Laroprovstat · Rosuvastatin · Bempedoic acid

Start the discussion